FDA Public Meeting on Sarcopenia
On behalf of the Food and Drug Administration (FDA), we invite you and the senior community you interact with via your research and patient care efforts to an upcoming public meeting on sarcopenia to be held April 6, 2017 1pm to 5pm (EDT) at the Tommy Douglas Conference Center in Silver Spring, Maryland. Sarcopenia is a condition characterized by loss of muscle mass and loss of muscle function or strength that occurs with age.
Help make this meeting a success by encouraging patients to participate either in-person or through the live webcast. FDA needs your help to make this meeting a success. Please direct patients to the links below to register, explore the discussion questions and meeting format, and find more information on FDA’s Patient-Focused-Drug Development initiative.
Registration: https://sarcopeniapfdd.eventbrite.com Meeting website: Public Meeting on Patient-Focused Drug Development for Sarcopenia Background: Watching these webinars on FDA and Patient-Focused Drug Development in advance may be helpful in preparing for the meeting. The meeting format maximizes patient participation. For each discussion topic, a small panel of patients or caretakers will prove brief comments to start the dialogue. The panel comments will be followed by a facilitated discussion with other patients and patient representatives in the audience. Patients or caregivers who would like to be considered to be on the opening panel can indicate that as part of registration. They will be asked to send a short summary of their responses to the discussion questions (posted on our registration site) to PatientFocused@fda.hhs.gov.
Registration: https://sarcopeniapfdd.eventbrite.com
Meeting website: Public Meeting on Patient-Focused Drug Development for Sarcopenia
Background: Watching these webinars on FDA and Patient-Focused Drug Development in advance may be helpful in preparing for the meeting.
The meeting format maximizes patient participation. For each discussion topic, a small panel of patients or caretakers will prove brief comments to start the dialogue. The panel comments will be followed by a facilitated discussion with other patients and patient representatives in the audience. Patients or caregivers who would like to be considered to be on the opening panel can indicate that as part of registration. They will be asked to send a short summary of their responses to the discussion questions (posted on our registration site) to PatientFocused@fda.hhs.gov.
